1-3 of 3
Eric Wu, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

An Adaptive, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)

Kenneth W. Wood, PhD, James Geib, BS, Eric Wu, PhD, Jason Berlin, MS, Irena Webster, MPH, MA, Kenneth I. Ataga, MD, Jo Howard, MBBChir, MRCP, FRCPath, Jeremie H. Estepp, MD, Marilyn J. Telen, MD, Julie Brevard, MPH
Journal: Blood
Blood (2020) 136 (Supplement 1): 19–20.
https://doi.org/10.1182/blood-2020-134266
Published: 2020
Journal Articles

FT-4202, an Allosteric Activator of Pyruvate Kinase-R, Demonstrates Proof of Mechanism and Proof of Concept after a Single Dose and after Multiple Daily Doses in a Phase 1 Study of Patients with Sickle Cell Disease

R. Clark Brown, MD PhD, Kimberly Cruz, MD MS, Theodosia A. Kalfa, MD PhD, Frans A. Kuypers, PhD, Santosh L. Saraf, MD, Jeremie H. Estepp, MD, Luke R. Smart, MD, Punam Malik, MD, Mark Lerman, MD, Renae Mayer, MD, Maria D. Ribadeneira, PhD, Sanjeev Forsyth, MS, Patricia Schroeder, PhD, Eric Wu, PhD, Patrick Kelly, MD, Marilyn J. Telen, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 19–20.
https://doi.org/10.1182/blood-2020-134269
Published: 2020
Journal Articles

The Healthcare Resource Utilization, Costs, and Predictors of Progression Among Relapsed and Refractory CLL Patients

Annie Guerin, MSc, Saurabh Ray, PhD, Genevieve Gauthier, MSc, Ling-I Hsu, PhD, Maryia Zhdanava, Eric Wu, PhD
Journal: Blood
Blood (2015) 126 (23): 3313.
https://doi.org/10.1182/blood.V126.23.3313.3313
Published: 2015